Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of PDR001 in combination with MCS110 in gastric cancer
KCT0003237Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab, lacnotuzumab in gastric cancer (GC), sponsored by Novartis. Started Jan 2019; status: completed.
02
Drugs
spartalizumablacnotuzumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0003237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003237.